Information Provided By: 
Fly News Breaks for November 6, 2018
SAGE
Nov 6, 2018 | 14:18 EDT
Piper Jaffray analyst Danielle Brill, who maintained an Overweight rating and $206 price target on Sage Therapeutics shares, noted that the announced plans to price Zulresso at $25,000-$35,000 per course -- should it be approved on its December 19 PDUFA date -- which is at a premium to Piper's estimated net pricing of $15,000. Brill also noted that the drug's sales force has been hired, which includes ~130 reps, and ~50 patient support/access personnel, and she is awaiting final commercial details following PDUFA announcement.
News For SAGE From the Last 2 Days
There are no results for your query SAGE
